ClinicalTrials.Veeva

Menu

Risk Factor Involved in Knee Osteoarthritis (KOA)

I

Iacob Czihac Emergency Military Clinical Hospital

Status

Completed

Conditions

Knee Osteoarthritis

Treatments

Other: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Other: The influence of ROS from the synovial fluid on the severity of KOA
Other: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT05749601
10/A575

Details and patient eligibility

About

Clinical study regarding the incidence and severity of knee osteoarthritis (KOA) in a certain area from South-Eastern Europe. Aim of the clinical study: to determine the KOA grade through X-Ray studies, to perform nuclear magnetic resonance (NMR) analysis to assess the KOA severity and to determine the level of significant parameters in the synovial liquid extracted from the patients presenting KOA.

Full description

Clinical study regarding the incidence and severity of KOA in a certain area from South-Eastern Europe. Clinical study on 85 patients out 373 participants that were screened, chosen based on inclusion/exclusion criteria.

Aim of the clinical study: to determine the KOA grade through X-Ray studies, to perform nuclear magnetic resonance (NRM) analysis to assess the KOA severity. Data corroboration of the KOA degree with the results of the blood samples analysis, looking for the influence of the metabolic syndrome (MetS) parameters - high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides, glycemia, and then the body mass index (BMI). In the meantime, there is intended to associate the environment of origin of the patients from the trial group with the KOA incidence and severity. To determine the level of significant parameters in the synovial liquid extracted from the patients presenting KOA, analysis of the degradation products present in the synovial fluid of patients with KOA, such as free radicals, like reactive oxygen species (ROS) and reactive nitrogen species (RNS) and their influence on the severity of the pathology.

Enrollment

85 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • male and female with knee pain (complaints); presented symptoms and clinical signs corresponding to KOA and had knee X-rays in the anteroposterior view and nuclear magnetic resonance (NMR) performed for setting the diagnosis with unilateral or bilateral knee pain; patients with clinically determined and recorded values of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides and the glycemia in the clinical observation sheet.

Exclusion criteria

  • patients presenting lower limb arthroplasties; history of lower limb or pelvis fractures and previous knee surgery: ligamentoplasty, meniscectomy; inflammatory rheumatic diseases such as rheumatoid polyarthritis; other major conditions like malignant illness.

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

85 participants in 5 patient groups

Patients without knee osteoarthritis (KOA) grade 0
Active Comparator group
Description:
Patient without knee affection
Treatment:
Other: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Other: The influence of ROS from the synovial fluid on the severity of KOA
Other: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis
Patients with KOA grade I
Experimental group
Description:
Kellgren-Lawrence classification (KL) grade I- doubtful narrowing of the joint space and possible osteophytes
Treatment:
Other: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Other: The influence of ROS from the synovial fluid on the severity of KOA
Other: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis
Patients with KOA grade II
Experimental group
Description:
KL grade II - definite osteophytes and possible narrowing of joint space.
Treatment:
Other: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Other: The influence of ROS from the synovial fluid on the severity of KOA
Other: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis
Patients with KOA grade III
Experimental group
Description:
KL grade III- definite narrowing of the joint space, significant osteophytosis, and possible bone deformities.
Treatment:
Other: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Other: The influence of ROS from the synovial fluid on the severity of KOA
Other: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis
Patients with KOA grade IV
Experimental group
Description:
KL grade IV- marked joint space narrowing accompanied by deformities, bone sclerosis, and large osteophytes
Treatment:
Other: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Other: The influence of ROS from the synovial fluid on the severity of KOA
Other: The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems